Published online May 16, 2022. doi: 10.12998/wjcc.v10.i14.4704
Peer-review started: December 24, 2021
First decision: January 25, 2022
Revised: February 6, 2022
Accepted: March 26, 2022
Article in press: March 26, 2022
Published online: May 16, 2022
Processing time: 139 Days and 19.1 Hours
Growing teratoma syndrome (GTS) is an unusual presentation of an amazing transformation of teratoma from malignant to benign on pathology during or after systemic or intraperitoneal chemotherapy. The definitive pathogenesis is still not fully understood due to the lack of large-sample studies.
A 53-year-old woman underwent radical surgery and postoperative intraperitoneal chemotherapy due to immature teratoma of the right ovary at the age of 28. She remained well during a 25-year follow-up period after surgery. Multiple asymptomatic solid masses were found in the liver on ultrasonography a month ago. Enhanced computed tomography (CT) of the abdomen revealed multiple masses in the abdominal cavity. The largest one was located in the posterior peritoneum next to the sixth segment of the right liver, about 7.9 cm × 7.5 cm in size. Three masses were present inside the liver, and one mass was in the right pelvic floor. Multiple lumps in the abdominal cavity were completely removed by surgery. During the operation, multiple space-occupying lesions were seen, ranging in size from 0.5 to 3 cm, and grayish white in color and hard in texture. Ovarian GTS was finally diagnosed based on postoperative pathology. After surgery, she recovered uneventfully. During a 3-year follow-up, the patient remained free of the disease without any recurrence on CT scan.
GTS is a rare phenomenon characterized by conversion of immature teratoma to mature one during or after chemotherapy and presents as growing and meta
Core Tip: Growing teratoma syndrome (GTS) is a rare complication characterized by normal tumor markers during or after chemotherapy, but the size or number of tumor increases or both increases. At present, the mechanism has not yet been explained. In this regard, we propose a new hypothesis of tumor competitive inhibition and dormancy. It is recommended that clinicians should know the characteristics of the course of the disease, closely follow up the patients, diagnose and treat the disease timely, and avoid unnecessary chemotherapy. Surgical resection is the key to ensure a good prognosis of ovarian GTS.